X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

X4 Pharmaceuticals reports positive trial results and financial resilience

X4 Pharmaceuticals showcased strong clinical performance with positive trial results for mavorixafor, while also strengthening its financial position despite reporting a net loss.
The company faces challenges in managing R&D expenses and addressing ongoing financial losses, but opportunities lie in market expansion and regulatory progress for mavorixafor.
By navigating challenges effectively and capitalizing on opportunities, X4 Pharmaceuticals can position itself for growth and success in advancing its lead candidate to market.
Investor interest, regulatory milestones, and strategic partnerships will play key roles in shaping X4 Pharmaceuticals' future trajectory and market competitiveness.

X4 Pharmaceuticals reports successful Phase III trial and plans FDA filing

X4 Pharmaceuticals demonstrated significant progress with mavorixafor and plans for regulatory filings, supported by a healthy cash position.
While facing challenges in managing expenses and achieving profitability, the company remains focused on advancing its pipeline and engaging with stakeholders.
Opportunities lie in upcoming events for collaboration and data dissemination, signaling potential growth avenues for X4 Pharmaceuticals.
Overall, X4 Pharmaceuticals' Q1 2023 earnings call highlighted achievements, financial standing, challenges, and future prospects for investors and stakeholders.

X4 Pharmaceuticals reports strong Q2 results and advances mavorixafor trials

X4 Pharmaceuticals showcased positive trial results and financial strength, positioning the company for future growth and market success.
While facing challenges in upcoming trials and commercialization, the company's strategic leadership and product potential offer opportunities for expansion.
Navigating regulatory processes and market dynamics will be key to realizing the full potential of mavorixafor and driving long-term value for stakeholders.
Overall, X4 Pharmaceuticals' focus on innovation, strategic partnerships, and market insights bode well for their competitive positioning and growth trajectory.

X4 Pharmaceuticals poised for mavorixafor launch in 2024

X4 Pharmaceuticals is on track for a significant mavorixafor launch in 2024, backed by strong financials and strategic initiatives. Challenges in patient diagnosis and access require focused efforts post-approval.

X4 Pharmaceuticals reports milestone achievements and financial stability for growth

X4 Pharmaceuticals showcased strong clinical advancements and financial stability in 2023, positioning them for potential FDA approval and market expansion.
While facing challenges in managing expenses and addressing stakeholder queries, the company remains optimistic about revenue opportunities and growth prospects.
With a focus on regulatory milestones, market entry strategies, and revenue generation, X4 Pharmaceuticals aims to capitalize on the momentum from their achievements.

X4 Pharmaceuticals reports FDA approval for XOLREMDI, faces financial challenges

X4 Pharmaceuticals faces financial challenges with a significant net loss despite having a substantial cash position.
The FDA approval of XOLREMDI for WHIM syndrome highlights the company's progress in drug development.
Opportunities lie in expanding XOLREMDI's market reach, monetizing PRV, and advancing R&D efforts for future growth.

X4 Pharmaceuticals excels in Phase II study and FDA approval, eyes market expansion in 2025

X4 Pharmaceuticals showcased positive results from the Phase II study of mavorixafor and FDA approval for XOLREMDI, signaling significant advancements in product development and market penetration.
While challenges exist in transitioning to Phase III trials and ensuring successful commercialization, the company's focus on physician comfort, disease awareness, and patient education presents opportunities for growth.
Overall, X4 Pharmaceuticals is well-positioned to capitalize on its recent achievements and drive further success through strategic initiatives in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

X4 Pharmaceuticals, Inc. is a late clinical-stage company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. Its clinical candidate is mavorixafor. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

X4 to host virtual investor event on Tuesday, May 16 CIS oral presentation to take place on Sunday, May 21 BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that its submitted late-breaker abstract entitled "Results of a Phase 3 Trial of an Oral CXCR4 Antagonist, Mavorixafor, for Treatment of Patients With WHIM Syndrome" has been accepted for oral presentation at the Annual Meeting of the Clinical Immunology Society (CIS), which is taking place May 18-21, 2023, in St. Louis, MO. New data related to clinical secondary endpoints, among other assessments, are to be presented.

X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)

Positive P3 results of mavorixafor for first-ever treatment of WHIM syndrome with possible BLA approval in 1H 2024. A large chronic neutropenia market could see their first approved drug in over 30 years.

X4 Pharmaceuticals: Chronic Neutropenia Might Finally Have Met Its Match

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q4 2022 Earnings Conference Call March 21, 2023 9:00 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Paula Ragan - CEO Adam Mostafa - CFO Murray Stewart - Interim Chief Medical Officer Mark Baldry - Chief Commercial Officer Conference Call Participants Divya Rao - TD Cowen Edward Tenthoff - Piper Sandler Kristen Kluska - Cantor Fitzgerald Swayampakula Ramakanth - H.C. Wainwright Operator Thank you for standing by.

X4 Pharmaceuticals, Inc. (XFOR) Q4 2022 Earnings Call Transcript

Upcoming expected milestones for investigational therapy mavorixafor in WHIM syndrome include: presentation of additional Phase 3 clinical data in 2Q 2023, NDA submission in early

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the fourth quarter and twelve months ended December 31, 2022 on March 21, 2023.

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock

Akebia Therapeutics

Astra Space

SoFi Technologies

Volitionrx Limited

Exicure Inc

Insiders are buying these penny stocks but are they worth the risk? The post Penny Stocks To Buy: 6 Insider Picks Before 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 6 Insider Picks Before 2023

Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia

X4 Pharmaceuticals' Presentations at ASH 2022 Further Highlight Opportunity for Mavorixafor in the Treatment of Chronic Neutropenia

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today the pricing of its previously announced underwritten public offering of 52,300,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,800,000 shares of its common stock, and accompanying Class C warrants to purchase 29,550,000 shares of its common stock at an exercise price of $1.50 per share of common stock (or, for investors who so choose, pre-funded warrants to purchase shares of its common stock) at a price to the public of $1.10 per share and accompanying Class C warrant (or $1.099 per pre-funded warrant and accompanying Class C warrant). X4 has also granted the underwriters a 30-day option to purchase up to an additional 8,865,000 shares of its common stock and/or Class C warrants to purchase up to an additional 4,432,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. X4's gross proceeds from this offering are expected to be approximately $65.0 million (or approximately $74.8 million if the underwriters exercise their option in full), before deducting underwriting discounts and estimated offering expenses and any proceeds from the exercise of the warrants to be issued in the offering. All of the securities in the offering are being sold by X4. The offering is expected to close on or about December 9, 2022, subject to customary closing conditions.

X4 Pharmaceuticals Prices $65.0 Million Public Offering

BOSTON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof) and accompanying warrants to purchase shares of its common stock (or pre-funded warrants). In addition, X4 expects to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering will be sold by X4. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

X4 Pharmaceuticals Announces Proposed Public Offering

4WHIM trial meets primary endpoint and first key secondary endpoint, with mavorixafor achieving statistically significant and clinically relevant longer times above threshold levels for both absolute neutrophil (P

X4 Pharmaceuticals Announces Positive Top-Line Results from 4WHIM Global, Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced that management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 15, 2022.

X4 Pharmaceuticals to Present at Stifel Healthcare Conference

BOSTON--(BUSINESS WIRE)--Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the formation of its Clinical Scientific Advisory Board (“Clinical SAB”).

Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Diego Cadavid - Chief Medical Officer Mark Baldry - Chief Commercial Officer Murray Stewart - Interim Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Eva Privitera - Cowen Mayank Mamtani - B. Riley Securities Trevor Allred - Oppenheimer Swayampakula Ramakanth - H.C.

X4 Pharmaceuticals, Inc. (XFOR) Q3 2022 Earnings Call Transcript

Following positive mavorixafor Phase 1b data release in multiple chronic neutropenic disorders, X4 continues to look forward to top-line results from its pivotal Phase 3 trial in WHIM syndrome in the fourth quarter of 2022

X4 Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022

X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the third quarter ended September 30, 2022 on November 3, 2022.

X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022

100% of study participants (n=25) achieved robust responses to oral mavorixafor

X4 Pharmaceuticals Announces New Positive Phase 1b Data Supporting Mavorixafor's Broad Potential in Chronic Neutropenia (CN)

X4 Pharmaceuticals is advancing Mavorixafor, a once-daily oral dose, first in class, small molecule antagonist of the CXCR4 receptor in WHIM syndrome and in chronic neutropenia disorders. On Sept 27, topline results will be presented from a Phase 1b trial testing Mavorixafor with or without G-CSF in patients with chronic neutropenia including severe congenital, idiopathic or cyclic.

X4 Pharmaceuticals: Upcoming Catalysts

Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&A Webcast to take place on September 27 at 8:00 a.m. ET, followed by live Q&A

X4 Pharmaceuticals to Host Investor Webinar Highlighting New Mavorixafor Phase 1b Data in Chronic Neutropenia

All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy

BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will present a corporate overview at the Canaccord Genuity 42nd Annual Growth Conference being held in Boston, MA, from August 8-11, 2022.

X4 Pharmaceuticals to Present at Canaccord Genuity's 42nd Annual Growth Conference

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dr. Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Art Taveras - Chief Scientific Officer Diego Cadavid - Chief Medical Officer Mary DiBiase - Chief Operating Officer Conference Call Participants Stephen Willey - Stifel Eva Privitera - Cowen Mayank Mamtani - B. Riley Securities Arthur He - H.C.

X4 Pharmaceuticals, Inc.'s (XFOR) CEO Dr. Paula Ragan on Q2 2022 Results - Earnings Call Transcript

Highlights notable upcoming milestones including data from Phase 1b trial in chronic neutropenia, expected in late September, and results from global, pivotal Phase 3 trial in WHIM syndrome, expected in 4Q 2022

X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the second quarter ended June 30, 2022, and provide an update on recent business highlights, on August 4, 2022.

News for X4 Pharmaceuticals Inc Stock (XFOR)